- Advanced search
|Approved drug?||Yes (source: FDA (2004), EMA (2006))|
|International Nonproprietary Names|
|Search PubMed clinical trials||natalizumab|
|Search PubMed titles||natalizumab|
|Search PubMed titles/abstracts||natalizumab|
|Natalizumab was the first migration-inhibitory biological drug to be approved for inflammatory diseases.
Targeting cell migration-related molecules in immune conditions (and cancer) is regarded as a significant new focus for the development of novel anti-inflammatory therapeutics .
The design and synthesis of this antibody is described in , but the article is not open access.